1990 Volume 31 Issue 5 Pages 500-503
In order to prevent progression of acute non-A, non-B hepatitis, we have conducted a controlled trial with interferon. Eleven patients were treated with beta interferon, and 14 patients were served as untreated control. Chronicity rate at 12 month was 36% and 100% in treated and untreated, respectively. At 18 month of follow-up, 22% of treated and 100% of untreated patients with acute non-A, non-B hepatitis showed continued abnormality of liver function test. In addition, negative turn of anti-HCV antibody was observed in 3 of 6 in treated and in none of 9 untreated patients. These study revealed interferon treatment in acute phase may prevent the progression to chronicity.
